Matching slides 303,780
Current window 213,391-213,420
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

213,391-213,420 of 303,780

filter-aware
15
The slide serves as a visual product showcase without text-based claims or data.Berkeley Lights | Investor Presentation Deck | 15 slides · PhenomeX
Pitch deck Investor relations 1 hit
01
Slide 1
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
02
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
03
The slide uses a linked-circle diagram to represent the company's core pillars.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
04
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Team1 hit
05
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Team1 hit
06
The slide uses a visual comparison between healthy cells (alkaline) and cancer cells (acidic) to demonstrate the selective binding mechanism.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a Gantt-style visualization to represent clinical trial phases for multiple drug candidates.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
09
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Roadmap1 hit
10
The slide uses a structured list format to define the target market and unmet medical need.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
11
Includes a waterfall plot for partial response and a spider plot for longitudinal tumor change.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
13
Includes specific clinical trial design details (dosing regimens, patient counts, endpoints).BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
14
The slide uses a decision tree/process flow to map patient cohorts to clinical outcomes and subsequent trial progression.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
16
Includes detailed footnotes for data sources and medical abbreviations.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
17
The chart is a classic waterfall plot used in oncology to show tumor shrinkage/growth.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
The slide uses a process-oriented layout to describe clinical trial progression.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
Includes abbreviations for LMS, UPS, and NSCLC at the bottom.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
25
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
26
The slide uses a grid of metrics to establish the total addressable market and the specific sub-segment (2L+ ROR2+ patients) targeted by the company.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
27
The chart displays 'Maximum % Change from Baseline in Sum of Target Lesions'.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
28
Uses a 2x2 grid layout to present key epidemiological and clinical data points.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
30
The slide uses a structured layout to define the patient funnel and clinical need.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
31
The slide presents clinical data points (PR/CR rates) to justify moving to Phase 2.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
32
The slide uses a side-by-side comparison layout to detail patient cohorts and treatment regimens for different indications.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
35
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-based process diagram to show dose escalation and RP2D selection.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
38
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
41
The slide uses a table structure to represent a timeline of events.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations Loop · Why Now1 hit
42
The slide uses a linked-circle diagram to represent the company's core pillars.BioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit
43
BioAtla | Investor Presentation Deck | 44 slidesBioAtla | Investor Presentation Deck | 44 slides · BioAtla
Pitch deck Investor relations 1 hit